PMCB

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

PharmaCyte Biotech Inc

NASDAQ | PMCB

1.00

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 14, 2025)

$6.80M

Market Cap

16.67

P/E Ratio

0.06

EPS

$2.42

52 Week High

$0.80

52 Week Low

HEALTHCARE

Sector

PMCB Chart

Recent Chart
Price Action

PMCB Technicals

Tags:

PMCB Earnings

Yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.4M
Selling General And Administrative $3.9M
Research And Development $438K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income $1.4M
Interest Income $1.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $31M
Comprehensive Income Net Of Tax -
Ebit -$4.4T
Ebitda $31M
Net Income $31M

Revenue & Profitability

Earnings Performance

PMCB Financials

yearly Balance Sheet (As of Apr 30, 2025)

Field Value (USD)
Total Assets $55M
Total Current Assets $22M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables $3.7M
Total Non Current Assets $33M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $1.5M
Intangible Assets Excluding Goodwill $1.5M
Goodwill -
Investments -
Long Term Investments $22M
Short Term Investments $366K
Other Current Assets $3.1M
Other Non Current Assets -
Total Liabilities $3.3M
Total Current Liabilities $2.9M
Current Accounts Payable $399K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $363K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $2.5M
Other Non Current Liabilities -
Total Shareholder Equity $52M
Treasury Stock -
Retained Earnings -$85M
Common Stock $2.2K
Common Stock Shares Outstanding $7.3M

yearly Cash Flow (As of Apr 30, 2025)

Field Value (USD)
Operating Cashflow -$3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $4
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$7M
Cashflow From Financing -$25M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $1.1M
Dividend Payout Common Stock $1.1M
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$25M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $31M

yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.4M
Selling General And Administrative $3.9M
Research And Development $438K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income $1.4M
Interest Income $1.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $31M
Comprehensive Income Net Of Tax -
Ebit -$4.4T
Ebitda $31M
Net Income $31M

PMCB News

PMCB Profile

PharmaCyte Biotech Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

PharmaCyte Biotech Inc. is a clinical-stage biotechnology company based in Laguna Hills, California, dedicated to pioneering cell therapies targeting cancer and diabetes. The company leverages its proprietary technologies to develop innovative treatments designed to improve patient outcomes and quality of life. With a strategic focus on advancing its clinical programs, PharmaCyte is positioned to play a significant role in the evolving landscape of biopharmaceutical therapies.

VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
BITF
+28.33%
$5.39
UGRO
+71.96%
$0.63
BURU
-21.69%
$0.40
YYAI
-21.23%
$0.13
INTC
+2.33%
$37.22
QBTS
+23.01%
$40.61
SSKN
+48.00%
$2.27
ITP
+17.48%
$0.30
NVTS
+20.93%
$12.05
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
CAN
+13.81%
$1.73
EDHL
+79.75%
$0.89
BYND
-22.73%
$0.79
LAES
+17.31%
$7.19
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
IONQ
+16.19%
$82.09
MNTS
+23.03%
$1.75
CRML
+20.74%
$28.10
KDLY
-1.56%
$0.85
RGTI
-4.27%
$52.55
RMBL
+60.50%
$3.21
JDZG
+32.97%
$2.50
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AMZN
+1.71%
$220.07
NAK
+2.63%
$2.73
IONZ
+10.03%
$2.53
SRM
+53.27%
$10.30
AMD
+1.83%
$220.40
DNN
-0.81%
$3.05
SMR
+14.72%
$45.02
UUUU
+6.41%
$25.29
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
GPUS
-9.48%
$0.38
UAMY
-0.26%
$16.66
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
NUAI
+35.36%
$3.18
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
ERIC
+17.07%
$9.56
ADAP
-15.26%
$0.15
WWR
+13.27%
$2.89
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
OPI
-16.97%
$0.20
GWH
-9.09%
$8.22
AREC
+30.09%
$6.47
KLG
-9.05%
$13.35
NIO
-4.28%
$6.87
CORZ
+3.72%
$19.21
ABAT
+5.16%
$9.69
IREN
+2.41%
$65.69
GRYP
-10.38%
$1.38
GWAV
+89.77%
$16.14
SOFI
-0.46%
$27.01
SOUN
+3.78%
$19.86
MODV
-25.22%
$0.43
MARA
+3.65%
$20.98
TLRY
-3.84%
$1.62
ACHR
-5.12%
$12.11
BBD
+1.67%
$3.14
RGTZ
+5.16%
$9.77
ELAB
+83.43%
$9.55
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
ATXS
+38.62%
$11.74
QS
-1.58%
$16.72
ONDS
-4.99%
$10.27
BMNR
-5.84%
$53.52
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
ASST
-5.54%
$1.02
F
+0.08%
$11.55
EXK
+10.96%
$8.50
PLTD
-1.00%
$6.91
BTBT
+0.75%
$4.03
VLY
+2.32%
$10.55
TBH
-48.33%
$1.24
DFLI
-1.68%
$1.54
NEHC
-9.61%
$2.35
SHOT
-74.37%
$0.39
EOSE
+2.05%
$17.39
RXRX
-3.79%
$5.32
GDXD
+1.06%
$0.74
NB
-3.88%
$10.88
ZAPP
-46.30%
$0.15
VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
BITF
+28.33%
$5.39
UGRO
+71.96%
$0.63
BURU
-21.69%
$0.40
YYAI
-21.23%
$0.13
INTC
+2.33%
$37.22
QBTS
+23.01%
$40.61
SSKN
+48.00%
$2.27
ITP
+17.48%
$0.30
NVTS
+20.93%
$12.05
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
CAN
+13.81%
$1.73
EDHL
+79.75%
$0.89
BYND
-22.73%
$0.79
LAES
+17.31%
$7.19
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
IONQ
+16.19%
$82.09
MNTS
+23.03%
$1.75
CRML
+20.74%
$28.10
KDLY
-1.56%
$0.85
RGTI
-4.27%
$52.55
RMBL
+60.50%
$3.21
JDZG
+32.97%
$2.50
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AMZN
+1.71%
$220.07
NAK
+2.63%
$2.73
IONZ
+10.03%
$2.53
SRM
+53.27%
$10.30
AMD
+1.83%
$220.40
DNN
-0.81%
$3.05
SMR
+14.72%
$45.02
UUUU
+6.41%
$25.29
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
GPUS
-9.48%
$0.38
UAMY
-0.26%
$16.66
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
NUAI
+35.36%
$3.18
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
ERIC
+17.07%
$9.56
ADAP
-15.26%
$0.15
WWR
+13.27%
$2.89
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
OPI
-16.97%
$0.20
GWH
-9.09%
$8.22
AREC
+30.09%
$6.47
KLG
-9.05%
$13.35
NIO
-4.28%
$6.87
CORZ
+3.72%
$19.21
ABAT
+5.16%
$9.69
IREN
+2.41%
$65.69
GRYP
-10.38%
$1.38
GWAV
+89.77%
$16.14
SOFI
-0.46%
$27.01
SOUN
+3.78%
$19.86
MODV
-25.22%
$0.43
MARA
+3.65%
$20.98
TLRY
-3.84%
$1.62
ACHR
-5.12%
$12.11
BBD
+1.67%
$3.14
RGTZ
+5.16%
$9.77
ELAB
+83.43%
$9.55
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
ATXS
+38.62%
$11.74
QS
-1.58%
$16.72
ONDS
-4.99%
$10.27
BMNR
-5.84%
$53.52
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
ASST
-5.54%
$1.02
F
+0.08%
$11.55
EXK
+10.96%
$8.50
PLTD
-1.00%
$6.91
BTBT
+0.75%
$4.03
VLY
+2.32%
$10.55
TBH
-48.33%
$1.24
DFLI
-1.68%
$1.54
NEHC
-9.61%
$2.35
SHOT
-74.37%
$0.39
EOSE
+2.05%
$17.39
RXRX
-3.79%
$5.32
GDXD
+1.06%
$0.74
NB
-3.88%
$10.88
ZAPP
-46.30%
$0.15
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.